CGMP Psilocybin

Bimatoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. The DMF is on file with the US FDA, Brazil, Canada and India.

Epoprostenol is a potent vasodilator and antiplatelet substance with a very short physiological half-life. It is used for the treatment of pulmonary hypertension. The DMF for Epoprostenol Sodium Salt is on file with the US FDA, Canada, Japan, Australia, Switzerland and most EU member states.

Cloprostenol sodium salt is used in veterinary medicine as a luteolytic agent for the induction of estrus and the treatment of reproductive disorders in cattle, swine, and horses. Cloprostenol sodium salt is manufactured at Cayman Pharma both in racemic form (CAS No.: 55028-72-3) and optically active form ...

Latanoprost is the most widely used prostaglandin for the treatment of elevated intraocular pressure in glaucoma. Latanoprost is manufactured at Cayman Chemical (Ann Arbor, MI, USA) and at Cayman Pharma (Czech Republic). GMP material from both Cayman Chemical and Cayman Pharma, which conforms to the USP, E...

Latanoprostene Bunod is a nitric oxide-donating FP receptor agonist; it can be used for the treatment of elevated intraocular pressure (IOP) in glaucoma. Latanoprostene Bunod is manufactured at Cayman Pharma, our Czech subsidiary. GMP material is available, and the DMF for Latanoprostene Bunod is available...

Psilocin is the active form of Psilocybin, a naturally occurring psychedelic prodrug produced by more than 200 species of fungi. Psilocin is manufactured at Cayman Chemical in Ann Arbor, MI via a fully synthetic route. GMP material appropriate for clinical trials is available.

(+)-Cloprostenol is the active enantiomer of Cloprostenol. Cloprostenol is used in veterinary medicine as a luteolytic agent for the induction of estrus and the treatment of reproductive disorders in cattle, swine, and horses. The ASMF for (+)-Cloprostenol (sodium salt) is on file in several EU member states.

ANN ARBOR, MI, SEPTEMBER 12, 2023—Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients (APIs), has been granted a Certification of Suitability to the monographs of the European Pharmacopoeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its latanoprost API, effective August 28th, 2023. Cayman Chemical is the first company in the USA to receive a CEP for latanoprost.

This leaflet presents cGMP API portfolio of Cayman Pharma and Cayman Chemical.